Top Story

BLAST: Blinatumomab may effectively combat minimal residual disease in ALL

December 19, 2014

SAN FRANCISCO — About 80% of patients with acute lymphoblastic leukemia experienced a minimal residual disease response after treatment with blinatumomab, according to study results.

Persistent minimal residual disease leads to poor prognosis in ALL, researcher Nicola Gokbuget, MD, head of the Study Center at Goethe University Hospital in Frankfurt, Germany, said during a presentation.

In the Journals

Addition of monoclonal antibody to reduced-intensity conditioning regimen effective in advanced B-cell lymphoma

December 18, 2014
The addition of the CD20-directed monoclonal antibody 90Y-Ibritumomab tiuxetan to a reduced-intensity fludarabine-based conditioning regimen followed by allogeneic…
In the Journals

High AKR1B10 protein expression showed promising survival rates for HCC

December 18, 2014
Among a cohort of Korean patients with hepatocellular carcinoma, high aldo-keto reductase 1B10 protein expression predicted longer recurrence-free and disease-specific…
Ian Krop In the Journals

Ado-trastuzumab emtansine significantly extended OS in HER-2–positive breast cancer with CNS metastases

December 18, 2014
Patients with HER-2–positive advanced breast cancer treated with ado-trastuzumab emtansine experienced similar rates of central nervous system progression as those…
Meeting News CoveragePerspective

Early thymic precursor immunophenotype does not affect T-cell ALL outcomes

December 18, 2014
SAN FRANCISCO — Children with T-cell acute lymphoblastic leukemia achieved favorable 5-year EFS and OS outcomes regardless of whether they expressed the early…
More News Headlines »
CME CNE
Low Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »
Meeting News Coverage Video
IBIS-I: Tamoxifen provides long-term protection for women at high risk for breast cancer

IBIS-I: Tamoxifen provides long-term protection for women at high risk for breast cancer

December 12, 2014
SAN ANTONIO — Erin W. Hofstatter, MD, director of the Breast Cancer Genetics and Prevention Program at Yale…
More »
CME
New Advances, New Options: Evaluating the Changing Landscape of Hemophilia

New Advances, New Options: Evaluating the Changing Landscape of Hemophilia to Optimize Patient Outcomes

This activity is supported by an educational grant from Biogen Idec.

The bleeding abnormalities associated with hemophilia can have devastating consequences for patients. Recent advances…
More »